Ann: Trading Halt, page-61

Amazing tech but really it has been quite poor capital management from the company. You can have a cure for cancer but if you don't know how to manage your capital properly the shareholders will never get to benefit from it. They should have anticipated the large capital needs, and secured the necessary funding from the start. Otherwise you keep going back to the market for more money with nothing to show for the prior raises, and this is the outcome. A rapid decline in the share price as investors become increasingly dismayed and pessimistic. If they had just ripped the Band-Aid off rather than peeling it off painfully slow they could have got the dilution and capital raising out of the way long ago, allowing the market to look forward to the P3 result and commercialisation rather than "when will the next capital raise happen?" This would have resulted in a far more optimistic investor base, which would likely have seen prices continue to move higher in anticipation of good news rather than lower in fear of the next bad (dilution) news.

Again, great tech, just annoyed at the execution by this company. It shouldn't be at these prices, the tech is far too good for such a low MC. The reason it is though is because of what I've said above.